Lung carcinoid tumours constitute approximately 1-2% of all pulmonary tumours. They are derived from enterochromaffin cells, which are also known as 'Kulchitsky cells' and generally have indolent growth and development patterns. Carcinoid tumours are categorized as typical or atypical, depending on the number of mitoses per high power field and the presence of necrosis. In terms of management, surgical resection has been recognized to be the standard treatment for pulmonary carcinoid tumours. To our knowledge, the da Vinci system and robotic surgery have not been applied in sleeve lobectomies and bronchoplasty for the removal of carcinoid tumours in the United Kingdom. Therefore, we present a case of a sleeve lobectomy with bronchoplasty procedure for the removal of a carcinoid tumour located in the left lower lobe of the patient. The bronchus was repaired using a V-lock suture & Prolene sutures with the surgery performed using the da Vinci robotic surgical system.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945663 | PMC |
| http://dx.doi.org/10.21037/jovs.2018.04.06 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of lymph node involvement in pulmonary carcinoids: a narrative review.
Transl Lung Cancer Res
December 2024
Department of Thoracic Surgery, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Background And Objective: Pulmonary carcinoids (PCs) represent a rare subset of neuroendocrine tumors (NETs) within the respiratory tract that exhibit unique characteristics and clinical behaviors. These tumors are currently staged according to the tumor-nodules-metastases (TNM) classification of non-small cell lung cancer (NSCLC), which brings their reliability into question. The aim of this study was to assess reliability of the current TNM staging of PCs and explore other relevant prognostic factors of patient outcomes.
View Article and Find Full Text PDFAtypical Small Cell Lung Cancer: A New Malignancy Characterized by Chromothripsis, Carcinoid Tumors, and Wild-type RB1 and TP53.
Cancer Discov
January 2025
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas.
Small cell lung cancer (SCLC) and pulmonary carcinoid tumors are traditionally seen as unrelated, with SCLC linked to smoking and characterized by biallelic loss of RB1 and TP53 and rapid progression. Rekhtman and colleagues upend these assumptions by discovering an "atypical" SCLC that arises in nonsmokers with intact RB1 and TP53 loci, chromothripsis-induced oncogene amplifications on extrachromosomal DNA, and frequent synchronous carcinoid tumors. See related article by Rekhtman et al.
View Article and Find Full Text PDFSafety and Efficacy of Transsternal Core Biopsy of Anterior Mediastinal Masses.
Ann Thorac Surg Short Rep
December 2024
Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Background: The study evaluated the safety and adequacy of percutaneous transsternal anterior mediastinal core biopsy.
Methods: All percutaneous computed tomography-guided transsternal mediastinal 18-gauge core biopsies performed at 2 academic centers were retrospectively reviewed. Procedural, clinical, and pathology data were recorded.
Atypical Carcinoid With Pulmonary Metastasis in an Adolescent.
Ann Thorac Surg Short Rep
December 2024
Department of Thoracic Surgery, International University of Health and Welfare Narita Hospital, Narita, Japan.
Advanced-stage atypical carcinoid tumors are seldom seen in the teenaged population. Comprehensive care, extending beyond mere cancer treatment, is essential. A 16-year-old boy received a diagnosis of a 13-mm nodule in the left S lung segment with signs suggesting interlobar pleural indentation.
View Article and Find Full Text PDFThe analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy.
Invest New Drugs
January 2025
Postgraduate Training Base Alliance, Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China.
A novel molecular classification for small cell lung cancer (SCLC) has been established utilizing the transcription factors achaete-scute homologue 1 (ASCL1), neurogenic differentiation factor 1 (NeuroD1), POU class 2 homeobox 3 (POU2F3), and yes-associated protein 1 (YAP1). This classification was predicated on the transcription factors. Conversely, there is a paucity of information regarding the distribution of these markers in other subtypes of pulmonary neuroendocrine tumors (PNET).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!